AbbVie, Inc. (ABBV)

In the past six months, AbbVie's stock experienced several notable events. As of January 13, 2026, the closing share price was $220.75, reflecting a 0.32% increase from the previous day, a 2.95% decrease over the past 30 days, and a 24.90% increase over the past 12 months. AbbVie announced an agreement with the Trump administration to lower drug prices for medicines like Alphagan, Combigan, Humira, and Synthroid, in exchange for a three-year exemption from import tariffs and a commitment to invest $100 billion in US R&D and capital investments. AbbVie secured an exclusive licensing deal with RemeGen for its bispecific cancer antibody candidate, RC148, gaining global rights outside Greater China. AbbVie entered a collaboration and license option deal with ADARx Pharmaceuticals to develop new RNA technology. AbbVie reported its Q3 2025 earnings on October 31st, with an EPS of $1.86 and revenue of $15.78 billion. Updated Q4 and FY2025 EPS guidance came in at or slightly below consensus, with IPR&D and related expenses expected to negatively impact Q4 EPS. The stock was also pressured by AbbVie's denial of reports regarding talks to acquire Revolution Medicines. The company recently increased its quarterly dividend to $1.73. Analyst ratings and price targets have varied.

AbbVie's business generally does not experience significant seasonality. However, product revenues can be influenced by end customer and retail buying patterns, as well as fluctuations in wholesaler inventory levels. In the United States, AbbVie primarily distributes its pharmaceutical products through independent wholesale distributors, with some direct sales to retailers, pharmacies, patients, and other customers. A substantial portion of its US pharmaceutical product sales in 2022 and 2024 were accounted for by three major wholesale distributors: McKesson Corporation, Cardinal Health, Inc., and AmerisourceBergen Corporation (2022) or Cencora, Inc. (2024). Outside the US, sales are predominantly made to wholesalers or through distributors, with reimbursement terms often negotiated through centralized national payer systems.

AbbVie Inc. is a diversified research-based biopharmaceutical company headquartered in North Chicago, Illinois, United States, operating within the biopharmaceutical, pharmaceuticals, and healthcare sectors. The company focuses on the discovery, development, manufacturing, and marketing of advanced therapies for complex and serious diseases, with a focus on therapeutic areas such as immunology, oncology, neuroscience, eye care, and aesthetics, as well as chronic rheumatological, gastroenterological, dermatological, neurological, viral, and metabolic diseases. Major products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Mavyret/Maviret, Norvir, Kaletra, Zinbryta, Alphagan, Combigan, and Synthroid.

AbbVie has a broad global presence, operating in over 70 countries across five world regions. The company maintains facilities in numerous countries, including the US, Canada, Mexico, China, Australia, Spain, France, the European Union, Japan, Brazil, Italy, Ireland, Costa Rica, Germany, and Singapore. Its research and development sites are located in places such as North Chicago, Illinois; Irvine, California; Cambridge and Worcester, Massachusetts; Ludwigshafen, Germany; and Tokyo, Japan.

In the past year, AbbVie's brand reputation has seen both positive and challenging aspects. The company was recognized as #15 in the inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List. AbbVie also partnered with the UAE's Ministry of Health to launch the 'Mental Health 360' campaign. However, AbbVie underperforms its industry peers in news mentions, ranking last. The company's reputation was also impacted by insider trading charges against a former Lazard banker related to AbbVie's $10.1 billion ImmunoGen acquisition. The recent drug pricing deals with the Trump administration could also influence public perception regarding drug affordability. Furthermore, AbbVie's performance in the 2022 Nature Benchmark was described as modest. Despite this, the company has reported a target to halve its absolute water withdrawal by 2035 and is actively reducing hazardous waste production.

Institutional investors hold a significant portion of AbbVie's shares, owning approximately 66% of the company, with the top 10 institutional investors collectively holding 36%. Overall institutional ownership stands at 73.22% of total shares outstanding. Retail investors and insiders account for about 34% of the company's ownership. Major institutional owners include Vanguard Group Inc., Blackrock, Inc., State Street Corp, JPMorgan Chase & Co., Morgan Stanley, Geode Capital Management, LLC, Capital Research Global Investors, Bank Of America Corp /de, Charles Schwab Investment Management Inc., and Fidelity Investments (FMR). Insiders own 0.15% of the company and have been net selling.